EL7.AI
StocksMediumUpdated×3•Originally published 2 October 2026•Updated 3 October 2026•
1 min read

Novartis Signs $7.8B RNA Therapeutics Deal with Abogen Biosciences

Handshake between Novartis and Abogen buildings with a DNA helix, lab equipment, and large $7.8B gold text.

Key Facts

1Novartis signed a licensing and collaboration agreement with Abogen Biosciences to develop RNA-encoded therapeutics.
2The total potential value of the deal reaches up to $7.8 billion, including upfront payments and developmental milestones.

Novartis signed a licensing and collaboration agreement with Abogen Biosciences to develop RNA-encoded therapeutics. Reuters reported that the total potential value of the deal reaches up to $7.8 billion, including upfront payments and various developmental milestones.

The partnership aims to bolster the Novartis pipeline in the high-growth sector of RNA-encoded drug development. NVSEF closed at $140.93 on September 30, 2026, prior to the announcement of this strategic expansion into new therapeutic technologies.

Latest Updates · 2

  1. Notable·

    Update: The financial terms of the agreement include a $575 million upfront payment from Novartis to Abogen Biosciences. The deal also grants an option to license the ABO2203 program, which targets B-cell non-Hodgkin lymphoma.

  2. Notable·

    Update: The partnership specifically focuses on developing mRNA-based therapeutics targeting autoimmune diseases. This specialization defines the scope of the collaboration, leveraging Abogen's technological platforms for these specific medical applications.